Radiotherapy for patients with localized hormone-refractory prostate cancer: Results of the Patterns of Care Study in Japan

BJU International

Volumn 104, Issue 10, 2009, Pages 1462-1466

  Sasaki, Tomonari ^a   Nakamura, Katsumasa ^b   Ogawa, Kazuhiko ^c   Onishi, Hiroshi ^d   Okamoto, Atsushi ^e   Koizumi, Masahiko ^f   Shioyama, Yoshiyuki ^g   Mitsumori, Michihide ^h   Teshima, Teruki ^e  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

^e Department of Medical Physics and Engineering ^*

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h KYOTO UNIVERSITY   (Japan)

Author keywords

Hormone refractory prostate cancer; Patterns of Care Study; Radiotherapy

Indexed keywords

ANTIANDROGEN; CISPLATIN; ESTRAMUSTINE; ESTROGEN; ETOPOSIDE; FLUOROURACIL; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; BLEEDING; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; COBALT THERAPY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; JAPAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ORCHIECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT INFORMATION; PELVIS; PHOTON THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROTEIN BLOOD LEVEL; PROTON THERAPY; RADIATION DOSE; RECURRENT CANCER; REGIONAL METASTASIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; UNIVERSITY HOSPITAL; URETER OBSTRUCTION; URETHRA STRICTURE; URINE INCONTINENCE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; EPIDEMIOLOGIC METHODS; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 72349087525     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08616.x     Document Type: Article

References (25)

1. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005 294 : 238 244
2. Labrie F, Cusan L, Gomez JL, Belanger A, Candas B. Long-term combined androgen blockade alone for localized prostate cancer. Mol Urol 1999 3 : 217 226
3. Immediate Versus Deferred Treatment for Advanced Prostatic Cancer. Initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997 79 : 235 246
4. Fowler JE Jr, Bigler SA, White PC, Duncan WL. Hormone therapy for locally advanced prostate cancer. J Urol 2002 168 : 546 549
5. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002 168 : 995 1000
6. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003 95 : 981 989
7. Kubota Y, Imai K, Yamanaka H. The correlation of stage and pathology of prostate cancer in Japan. Int J Urol 2000 7 : 139 144 (Pubitemid 30216380)
8. Kawakami S, Kawai T, Yonese J, Yamauchi T, Ishibashi K, Ueda T. [Palliative radiotherapy for local progression of hormone refractory stage D2 prostate cancer]. Nippon Hinyokika Gakkai Zasshi 1993 84 : 1681 1684
9. Nakamura K, Teshima T, Takahashi Y et al. Radical Radiation therapy for prostate cancer in Japan. A Patterns Care Study Report. Jpn J Clin Oncol 2003 33 : 122 126
10. Akaza H, Usami M, Hinotsu S et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol 2004 34 : 329 336
11. Yoshimi I, Mizuno S. Mortality trends of prostate cancer in Japan: 1960-2000. Jpn J Clin Oncol 2003 33 : 367
12. Zagars GK, Sands ME, Pollack A, von Eschenbach AC. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome. J Urol 1994 151 : 1330 1333
13. Lankford SP, Pollack A, Zagars GK. Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys 1995 33 : 907 912
14. Sanguineti G, Marcenaro M, Franzone P, Tognoni P, Barra S, Vitale V. Is there a 'curative' role of radiotherapy for clinically localized hormone refractory prostate cancer? Am J Clin Oncol 2004 27 : 264 268
15. Akimoto T, Kitamoto Y, Saito J et al. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes. Int J Radiat Oncol Biol Phys 2004 59 : 372 379
16. Nakamura K, Teshima T, Takahashi Y et al. Radiotherapy for localized hormone-refractory prostate cancer in Japan. Anticancer Res 2004 24 : 3141 3145
17. Nakamura K, Ogawa K, Yamamoto T et al. Trends in the practice of radiotherapy for localized prostate cancer in Japan: a preliminary patterns of care study report. Jpn J Clin Oncol 2003 33 : 527 532
18. Teshima T. Patterns of care study in Japan. Jpn J Clin Oncol 2005 35 : 497 506
19. Sasaki T, Nakamura K, Ogawa K et al. Postoperative radiotherapy for patients with prostate cancer in Japan; changing trends in national practice between 1996 and 98 and 1999-2001: Patterns of Care Study for Prostate Cancer. Jpn J Clin Oncol 2006 36 : 649 654
20. SAS. Procedure Reference. Version 6, 1st edn. Tokyo : SAS Institute in Japan, 1995
21. Oefelein MG, Agarwal PK, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 2004 171 : 1525 1528
22. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997 44 : 213 221 (Pubitemid 27405144)
23. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clinic Proc 2001 76 : 576 581
24. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001 19 : 1030 1039
25. Kraus PA, Lytton B, Weiss RM, Prosnitz LR. Radiation therapy for local palliative treatment of prostatic cancer. J Urol 1972 108 : 612 614